Browse the corpus

This activity discusses scopolamine, an antimuscarinic agent for managing motion sickness and postoperative nausea and vomiting. By focusing on scopolamine's mechanism of action, indications, and contraindications, healthcare professionals gain essential insights for efficacious patient care. By exploring scopolamine's pharmacokinetics, adverse event profile, and pertinent interactions, participants will adeptly navigate prescribing decisions, ensuring tailored treatment strategies and minimized adverse reactions. This program underscores the importance of understanding scopolamine's pharmacology in optimizing patient outcomes, empowering healthcare professionals to deliver personalized care with heightened precision. Objectives: Evaluate the mechanism of action of antimuscarinic antiemetics. Identify the administration method of antimuscarinic antiemetics. Assess the adverse drug reactions of antimuscarinic antiemetics. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients receiving antimuscarinic antiemetics. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Tachycardia, lethargy, convulsion, visual disturbance, dry flushed skin, dry mouth, urinary retention, agitation, coma, supraventricular arrhythmias, confusion, and hallucinations are signs and symptoms of anticholinergic toxicity. Management of Overdose The reversal of scopolamine toxicity is not a widely reported topic. However, based on the mechanism of toxicity, physostigmine can be used to reverse anticholinergic symptoms. There are reports of the use of physostigmine in cases of scopolamine toxicity.[40][10][40] The patient then requires monitoring for a cholinergic crisis with atropine available at the bedside. As with most poisonings, vital signs and echocardiogram should be obtained and monitored.[41][42]

Postoperative nausea and vomiting is a ubiquitous presentation when caring for postoperative patients. The incidence is estimated to be about 30% in the average patient and can rise as high as 70% in the high-risk patient. PONV is a significant concern because it prolongs recovery room time and can lead to increased hospital admissions and unanticipated complications. Additionally, the prevention of PONV is vital to the patient's mental well-being. A patient's risk of experiencing PONV can be reliably anticipated and predicted using several measures, including the Apfel score. In patients with increased risk, a multimodal approach, including the use of multiple antiemetic medications, is the proper approach to the prevention of PONV.[5] One potential antiemetic medication that has shown effectiveness in reducing the incidence of PONV is the transdermal scopolamine patch.[43] Due to the scopolamine patch's pharmacokinetics and pharmacodynamics, it must be applied several hours before the start of the patient's surgery. The patch can also be applied the previous night. The patient's healthcare team must remain vigilant about identifying patients at high risk for PONV. If scopolamine is indicated, there is sufficient time before the procedure to administer the drug effectively. Scopolamine commonly causes dry mouth, blurred vision, and sedation. As an antimuscarinic medication, scopolamine has the potential to cause anticholinergic symptoms, including tachycardia, urinary retention, and acute angle-closure glaucoma. There are also reports of withdrawal symptoms from the medication. The patient's healthcare team must recognize these potential complications and begin management as soon as possible; this is especially true for older patients at increased risk of complications, including falls.[10][33][43][44][43]

Due to the scopolamine patch's pharmacokinetics and pharmacodynamics, it must be applied several hours before the start of the patient's surgery. The patch can also be applied the previous night. The patient's healthcare team must remain vigilant about identifying patients at high risk for PONV. If scopolamine is indicated, there is sufficient time before the procedure to administer the drug effectively. Scopolamine commonly causes dry mouth, blurred vision, and sedation. As an antimuscarinic medication, scopolamine has the potential to cause anticholinergic symptoms, including tachycardia, urinary retention, and acute angle-closure glaucoma. There are also reports of withdrawal symptoms from the medication. The patient's healthcare team must recognize these potential complications and begin management as soon as possible; this is especially true for older patients at increased risk of complications, including falls.[10][33][43][44][43] A collaborative healthcare team approach is the best method for addressing PONV. Clinicians should accurately identify which patients will be candidates for antiemetic prophylaxis or therapy and coordinate with nurses and pharmacists for its delivery. Nurses will be administering the medication and should fully understand the points discussed in this activity regarding proper administration and handling of the drug, particularly in patch form. The pharmacist should complete a full drug-drug interaction check and verify dosing while also watching for mitigating factors like age that may require therapy modification. The pharmacist and nurse will report any issues or concerns to the treating clinician. These points highlight some of how an interprofessional team approach will be most successful in providing PONV care. Finally, a common mechanism of ophthalmic symptoms from scopolamine is self-contamination by the patient. The interprofessional healthcare team, including the pharmacist, will counsel the patient on hand washing and proper hand hygiene after touching the scopolamine patch. In addition to the morbidity associated with the actual adverse effect, the clinical signs associated with unilateral mydriasis may often be misinterpreted, leading to misdiagnosis, increased costs, and delay of proper treatment.[2]